CNP 1061

Drug Profile

CNP 1061

Alternative Names: CMP 1061; CNP1061; GT 1061

Latest Information Update: 16 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cita NeuroPharmaceuticals
  • Class Antidementias; Nootropics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 14 Dec 2005 Cita-NeuroPharmaceuticals has been acquired and merged into Vernalis
  • 23 Jun 2005 Cita NeuroPharmaceuticals has completed a phase I trial in Canada
  • 14 Apr 2005 GB Therapeutics is now called Cita NeuroPharmaceuticals Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top